Net Profit Margins
Ascendis Pharma A/S’s revenue fell -47.24% since last year same period to $1.04Mn in the Q4 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated -10.78% fall in its revenue since last 3-months.
Ascendis Pharma A/S’s net profit fell -37.12% since last year same period to $-16.45Mn in the Q4 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated 9.89% jump in its net profits since last 3-months.
Ascendis Pharma A/S’s net profit margin fell -159.92% since last year same period to -1576.99% in the Q4 2016. On a quarterly growth basis, Ascendis Pharma A/S has generated -0.99% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Ascendis Pharma A/S’s earning per share (EPS) estimates for the current quarter stand at -2.6 - a 3.35% jump from last quarter’s estimates.
Ascendis Pharma A/S’s earning per share (EPS) estimates for the current year stand at -2.6.
Return on Assets (ROA)
Return on Equity (ROE)
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S’s return on assets (ROA) stands at -0.32.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S’s return on equity (ROE) stands at -1.02.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
Ascendis Pharma A/S
Tuborg Boulevard 12, Hellerup, Denmark, 2900
Jan Moeller Mikkelsen